<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35170268</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">2191-0251</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>35</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>26</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of pediatric endocrinology &amp; metabolism : JPEM</Title>
          <ISOAbbreviation>J Pediatr Endocrinol Metab</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clinical characteristics of polyglandular autoimmune syndromes in pediatric age: an observational study.</ArticleTitle>
        <Pagination>
          <StartPage>477</StartPage>
          <EndPage>480</EndPage>
          <MedlinePgn>477-480</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1515/jpem-2022-0050</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Polyglandular autoimmune syndromes (PAS) are characterized by the association of two or more autoimmune diseases (AID) and are classified into four types. PAS type 1 is more frequently manifested in childhood, but the prevalence of other PAS in children, less described in the literature, seems to be underestimated.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">This study aimed to evaluate the prevalence of PAS in a selected pediatric population of 879 children with Diabetes mellitus type 1 (DM1), autoimmune thyroid disease (AITD), and Addison's disease (AD) followed in our hospital for 10 years and describe and classify the manifestations of different PAS.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">We diagnosed 35 children with PAS, most fulfilled criteria for PAS type 3 (65.7%), and AITD was the AID more frequently detected (74.3%). PAS type 1 was not diagnosed in our sample. Patients with PAS manifested DM1 and AITD at a younger age than children with monoglandular pathology (7.7 vs. 9.3 years, p=0.04 and 7.7 vs. 13.1 years, p&lt;0.01).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This is the first study that analyzes the prevalence of different types of PAS in a pediatric population followed by endocrine pathologies, namely DM1, AD, and AITD. As PAS manifestations are often preceded by a long latency period characterized by the presence of autoantibodies, we reinforce the need to value these markers for timely diagnosis and to screen PAS in patients with AD throughout their lives.</AbstractText>
          <CopyrightInformation>© 2022 Walter de Gruyter GmbH, Berlin/Boston.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bouça</LastName>
            <ForeName>Bruno</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Endocrinology, Diabetes and Metabolism Department, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nogueira</LastName>
            <ForeName>Andreia</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatrics Department, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Caetano</LastName>
            <ForeName>Joana</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Endocrinology Diabetes and Growth Department, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cardoso</LastName>
            <ForeName>Rita</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Endocrinology Diabetes and Growth Department, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dinis</LastName>
            <ForeName>Isabel</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Endocrinology Diabetes and Growth Department, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mirante</LastName>
            <ForeName>Alice</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Endocrinology Diabetes and Growth Department, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D064888">Observational Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>J Pediatr Endocrinol Metab</MedlineTA>
        <NlmUniqueID>9508900</NlmUniqueID>
        <ISSNLinking>0334-018X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000224" MajorTopicYN="Y">Addison Disease</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003922" MajorTopicYN="Y">Diabetes Mellitus, Type 1</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016884" MajorTopicYN="Y">Polyendocrinopathies, Autoimmune</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Addison’ disease</Keyword>
        <Keyword MajorTopicYN="N">autoimmune thyroid disease</Keyword>
        <Keyword MajorTopicYN="N">polyglandular autoimmune syndromes</Keyword>
        <Keyword MajorTopicYN="N">type 1 diabetes mellitus</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>5</Hour>
          <Minute>54</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35170268</ArticleId>
        <ArticleId IdType="doi">10.1515/jpem-2022-0050</ArticleId>
        <ArticleId IdType="pii">jpem-2022-0050</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Husebye, ES, Anderson, MS, Kämpe, O. Autoimmune polyendocrine syndromes. N Engl J Med 2018;378:1132–41. https://doi.org/10.1056/nejmra1713301.</Citation>
        </Reference>
        <Reference>
          <Citation>Pham-Dobor, G, Hanák, L, Hegyi, P, Márta, K, Párniczky, A, Gergics, M. Prevalence of other autoimmune diseases in polyglandular autoimmune syndromes type II and III. J Endocrinol Invest 2020;43:1–9. https://doi.org/10.1007/s40618-020-01229-1.</Citation>
        </Reference>
        <Reference>
          <Citation>Neufeld, M, Blizzard, RM. Polyglandular autoimmune disease. In: Pinchera, A, Doniach, D, Fenzi, DF, Baschieri, L, editors. Autoimmune aspects of endocrine disorders. London, UK: Academic Press; 1980:357–65 pp.</Citation>
        </Reference>
        <Reference>
          <Citation>Betterle, C, Zanchetta, R. Update on autoimmune polyendocrine syndromes (APS). Acta Biomed 2003;74:9–33.</Citation>
        </Reference>
        <Reference>
          <Citation>Schneller, C, Finkel, L, Wise, M, Hageman, JR, Littlejohn, E. Autoimmune polyendocrine syndrome: a case-based review. Pediatr Ann 2013;42:203–8. https://doi.org/10.3928/00904481-20130426-12.</Citation>
        </Reference>
        <Reference>
          <Citation>Renzullo, A, Accardo, G, Esposito, D, De Bellis, A, Bizzarro, A, Romano, M. Hashimoto’s thyroiditis and entero-chromaffin-like cell hyperplasia: early detection and somatostatin analogue Treatment. Eur J Inflamm 2013;11:863–70. https://doi.org/10.1177/1721727X1301100329.</Citation>
        </Reference>
        <Reference>
          <Citation>Bain, A, Stewart, M, Mwamure, P, Nirmalaraj, K. Addison’s disease in a patient with hypothyroidism: Autoimmune polyglandular syndrome type 2. In: BMJ Case Reports; 2015, 2015:2–4 pp.</Citation>
        </Reference>
        <Reference>
          <Citation>Cutolo, M. Autoimmune polyendocrine syndromes. Autoimmun Rev 2014;13:85–9. https://doi.org/10.1016/j.autrev.2013.07.006.</Citation>
        </Reference>
        <Reference>
          <Citation>Kahaly, GJ. ‘Polyglandular autoimmune syndrome type II’. Presse Med 2012;41:e663–e670. https://doi.org/10.1016/j.lpm.2012.09.011.</Citation>
        </Reference>
        <Reference>
          <Citation>Bahceci, M, Tuzcu, A, Pasa, S, Ayyildiz, O, Tuzcu, S. Polyglandular autoimmune syndrome type III accompanied by common variable immunodeficiency. Gynecol Endocrinol 2004;19:47–50. https://doi.org/10.1080/09513590410001725279.</Citation>
        </Reference>
        <Reference>
          <Citation>Turkoglu, Z, Kavala, M, Kolcak, O, Zindanci, I, Can, B. Autoimmune polyglandular syndrome-3C in a child. Dermatol Online J 2010;16:8. https://doi.org/10.5070/d324p9n474.</Citation>
        </Reference>
        <Reference>
          <Citation>Zirilli, G, Santucci, S, Cuzzupè, C, Corica, D, Pitrolo, E, Salzano, G. Peculiarities of autoimmune polyglandular syndromes in children and adolescents. Acta Biomed 2017;88:271–5. https://doi.org/10.23750/abm.v88i3.5898.</Citation>
        </Reference>
        <Reference>
          <Citation>Kahaly, GJ, Frommer, L. Polyglandular autoimmune syndromes. J Endocrinol Invest 2018;41:91–8. https://doi.org/10.1007/s40618-017-0740-9.</Citation>
        </Reference>
        <Reference>
          <Citation>Valenzise, M, Aversa, T, Saccomanno, A, De Luca, F, Salzano, G. Epidemiological and clinical peculiarities of polyglandular syndrome type 3 in pediatric age’. Ital J Pediatr 2017;43:4–7. https://doi.org/10.1186/s13052-017-0386-4.</Citation>
        </Reference>
        <Reference>
          <Citation>Ruggeri, RM, Trimarchi, F, Giuffrida, G, Certo, R, Cama, E, Campennì, A. Autoimmune comorbidities in Hashimoto’s thyroiditis: different patterns of association in adulthood and childhood/adolescence. Eur J Endocrinol 2017;176:133–41. https://doi.org/10.1530/eje-16-0737.</Citation>
        </Reference>
        <Reference>
          <Citation>Aversa, T, Corica, D, Zirilli, G, Pajno, GB, Salzano, G, De Luca, F. Phenotypic expression of autoimmunity in children with autoimmune thyroid disorders. Front Endocrinol 2019;10:1–7. https://doi.org/10.3389/fendo.2019.00476.</Citation>
        </Reference>
        <Reference>
          <Citation>Kahaly, GJ. Polyglandular autoimmune syndromes. Eur J Endocrinol 2009;161:11–20. https://doi.org/10.1530/eje-09-0044.</Citation>
        </Reference>
        <Reference>
          <Citation>Robles, DT, Fain, PR, Gottlieb, PA, Eisenbarth, GS. The genetics of autoimmune polyendocrine syndrome type II. Endocrinol Metab Clin N Am 2002;31:353–68. https://doi.org/10.1016/s0889-8529(01)00015-9.</Citation>
        </Reference>
        <Reference>
          <Citation>Maclaren, N. Addison’s disease 2001. J Clin Endocrinol Metab 2001;86:2909–22.</Citation>
        </Reference>
        <Reference>
          <Citation>Quinkler, M. Addison’s disease. Med Klin Intensivmed Notfallmed 2012;107:454–9. https://doi.org/10.1007/s00063-012-0112-3.</Citation>
        </Reference>
        <Reference>
          <Citation>Schatz, DA, Winter, WE. Autoimmune polyglandular syndrome II: clinical syndrome and treatment. Endocrinol Metab Clin N Am 2002;31:339–52. https://doi.org/10.1016/s0889-8529(01)00012-3.</Citation>
        </Reference>
        <Reference>
          <Citation>Fichna, M, Fichna, P, Gryczyńska, M, Walkowiak, J, Zurawek, M, Sowiński, J. Screening for associated autoimmune disorders in Polish patients with Addison’s disease. Endocrine 2010;37:349–60. https://doi.org/10.1007/s12020-010-9312-x.</Citation>
        </Reference>
        <Reference>
          <Citation>Zelissen, PMJ, Bast, EJEG, Croughs, RJM. Associated autoimmunity in addison’s disease. J Autoimmun 1995;8:121–30. https://doi.org/10.1006/jaut.1995.0009.</Citation>
        </Reference>
        <Reference>
          <Citation>Neufeld, M, Maclaren, N, Blizzard, R. Autoimmune polyglandular syndromes. Pediatr Ann 1980;9:154–62. https://doi.org/10.3928/0090-4481-19800401-07.</Citation>
        </Reference>
        <Reference>
          <Citation>Dittmar, M, Kahaly, GJ. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab 2003;88:2983–92. https://doi.org/10.1210/jc.2002-021845.</Citation>
        </Reference>
        <Reference>
          <Citation>Salardi, S, Volta, U, Zucchini, S, Fiorini, E, Maltoni, G, Vaira, B. Prevalence of celiac disease in children with type 1 diabetes mellitus increased in the mid-1990s: an 18-year longitudinal study based on anti-endomysial antibodies. J Pediatr Gastroenterol Nutr 2008;46:612–4. https://doi.org/10.1097/mpg.0b013e31815d697e.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
